3 Stocks Pushing The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 67 points (0.4%) at 16,436 as of Friday, Aug. 8, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,992 issues advancing vs. 961 declining with 169 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the industry include Teva Pharmaceutical Industries ( TEVA), down 1.2%, Novo Nordisk A/S ( NVO), down 0.6% and Abbott Laboratories ( ABT), down 0.5%. Top gainers within the industry include Medivation ( MDVN), up 9.5%, Illumina ( ILMN), up 4.5%, Vertex Pharmaceuticals ( VRTX), up 1.9%, Valeant Pharmaceuticals International ( VRX), up 1.4% and Alexion Pharmaceuticals ( ALXN), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Pharmacyclics ( PCYC) is one of the companies pushing the Drugs industry lower today. As of noon trading, Pharmacyclics is down $3.82 (-3.2%) to $116.79 on average volume. Thus far, 795,051 shares of Pharmacyclics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $115.58-$120.02 after having opened the day at $119.01 as compared to the previous trading day's close of $120.61.

Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. Pharmacyclics has a market cap of $9.0 billion and is part of the health care sector. Shares are up 14.0% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Pharmacyclics a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pharmacyclics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including poor profit margins and feeble growth in the company's earnings per share. Get the full Pharmacyclics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Mylan ( MYL) is down $0.75 (-1.6%) to $45.74 on heavy volume. Thus far, 5.4 million shares of Mylan exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $45.23-$47.34 after having opened the day at $46.11 as compared to the previous trading day's close of $46.49.

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. Mylan has a market cap of $17.9 billion and is part of the health care sector. Shares are up 7.1% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts that rate Mylan a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Mylan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mylan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AstraZeneca ( AZN) is down $1.96 (-2.8%) to $68.05 on average volume. Thus far, 2.3 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $67.48-$69.77 after having opened the day at $69.58 as compared to the previous trading day's close of $70.01.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $89.5 billion and is part of the health care sector. Shares are up 17.9% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst that rates AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015

The 10 Biggest U.S. M&A Deals in 2015